Sanofi has filed a new drug application (NDA) with the US FDA for LixiLan, its investigational fixed-ratio combination of insulin glargine (Lantus) and the GLP-1 receptor agonist lixisenatide (Lyxumia). Sanofi also revealed that it redeemed a priority review voucher (PRV) with the filing, giving the NDA an expedited 6-month review if the submission is accepted by the FDA, instead of the standard 10-month review.
Sanofi paid $245m for the PRV, which it bought from Retrophin earlier this year. The voucher allows for a...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
